Two doses of Covaxin are 50 percent effective against the symptomatic disease. The findings are based on the study conducted between April 15 and May 15, at the height of India’s second wave of infections this year. Covaxin in clinical trials had an estimated efficacy of 65% when the more infectious Delta variant was taken into account. Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 percent efficacy against symptomatic disease and present no serious safety concerns. However, the latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi. From 15 April to 15 May, they were symptomatic and underwent an RT-PCR test for COVID-19 detection.
Researchers noted that the Delta variant was the dominant strain in India during the study period. It accounts for approximately 80 percent of all confirmed COVID-19 cases. Hyderabad-based Bharat Biotech developed Covaxin in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune. They are an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart. In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. Meanwhile, the World Health Organization (WHO) added the vaccine to its list of approved emergency use COVID-19 vaccines.
The latest study conducted during the second COVID-19 surge and in Authority offered Covaxin to all healthcare workers.
The latest study conducted during the second COVID-19 surge and in Authority offered Covaxin to all healthcare workers. Our study offers a more complete picture of how (Covaxin) performs in the field. It should be considered in the context of COVID-19 surge conditions in India, combined with the possible immune evasive potential of the Delta variant,” said Manish Soneja, Additional Professor of Medicine at AIIMS New Delhi. The COVID-19 vaccination center at AIIMS New Delhi exclusively offered Covaxin beginning 16 January this year. The AIIMS offered it to all of its 23,000 employees.
Researchers evaluated the effectiveness of the vaccine against symptomatic RT-PCR confirmed SARS-CoV-2 infection. However, Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2 infection. The virus that causes COVID-19, and 1,097 tested negative. The odds of vaccination with Covaxin were compared between cases and controls and adjusted for occupational exposure to COVID-19, previous SARS-CoV-2 infection, and infection dates.